PHOENIX, Arizona – May 24, 2021 – Humabiologics, a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers, is pleased to announce its non-exclusive US partnering agreement with VWR, part of Avantor, Inc.

Humabiologics develops and commercializes high quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening. VWR, part of Avantor, has thousands of quality products used daily in research laboratories around the world.

“Humabiologics provides affordable and more clinically-relevant human-derived biomaterials that allow researchers to advance the translational research of regenerative medicine therapies”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics. “Our partnership with VWR allows us to serve a broader life sciences customer base of industry partners and academic institutions.”

Humabiologics products are used by life science companies and academic researchers to develop innovative therapies that address debilitating diseases and improve the quality of life for patients.

The use of animal products in research can lead to poor translation aspects, irrelevant outcomes, and FDA regulatory hurdles that can slow the development of life science innovations. Humabiologics human-derived products are designed to address these challenges. Humabiologics developed proprietary processes to manufacture its products and only partners with FDA registered and accredited tissue banks around the US to utilize thoroughly screened donated human tissue that will not be used for transplant. Humabiologics product offering includes native human collagen, bone gelatin, and extracellular matrix.

Published* and ongoing collaborative data, utilizing these products by researchers around the world for different applications, highlighted the quality and relevance of the products for developing translational therapies.

“New and emerging heath solutions based on regenerative medical technologies have the potential to greatly improve the human condition,” said Joan Koerber-Walker, president & CEO of the Arizona Bioindustry Association. “Humabiologics offers a solution to a challenge that researchers face by providing access to high quality, stable supply of human biomaterials at an affordable price. By partnering with Avantor to deliver these products through VWR, Humabiologics is making it easier for researchers around the world to get the biomaterials they need to move this important science forward.”